Cargando…
Emergent data influences the risk/benefit assessment of hemophilia gene therapy using recombinant adeno-associated virus
After decades of investigation, gene therapy has received regulatory approval to treat hemophilia. However, since gene therapy investigations were initially conceived, other avenues of treatment have revolutionized the care of hemophilia. Emergent data is showing that gene therapy may not be as bene...
Autor principal: | Puetz, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667906/ https://www.ncbi.nlm.nih.gov/pubmed/38020165 http://dx.doi.org/10.3389/fmed.2023.1256919 |
Ejemplares similares
-
Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021) -
Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction
por: Sun, Junjiang, et al.
Publicado: (2022) -
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
por: Schiavoni, Mario, et al.
Publicado: (2019) -
Advances of adeno-associated virus applied in gene therapy to hemophilia from bench work to the clinical use
por: Pei, Xiaolei, et al.
Publicado: (2019) -
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
por: Ling, Chen, et al.
Publicado: (2011)